LOGIN  |  REGISTER

Moderna (NASDAQ: MRNA) Stock Quote

Last Trade: US$107.15 -3.44 -3.11
Volume: 1,981,758
5-Day Change: 3.95%
YTD Change: 7.74%
Market Cap: US$41.030B

Latest News From Moderna

Announces next-generation COVID-19 vaccine candidate as fourth respiratory vaccine to successfully meet its Phase 3 endpoints Expects two more Phase 3 readouts in 2024, including combination vaccine against flu and COVID-19, and vaccine against CMV Announces positive clinical trial data from three new vaccines against viruses that cause significant burden (Epstein-Barr virus, Varicella-Zoster virus, norovirus) and advances... Read More
mRNA-1283 induced a more robust immune response compared to Spikevax ® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083 CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation... Read More
CAMBRIDGE, MA / ACCESSWIRE / February 29, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that it will host its fifth annual Investor Event focused on vaccines and business updates on Wednesday, March 27, 2024. The presentation will begin at 9:00 a.m. ET. Moderna's Investor Event will include presentations from management on Moderna's pipeline of mRNA vaccines. A live webcast will be available under "Events and... Read More
CAMBRIDGE, MA / ACCESSWIRE / February 28, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced its participation in the following upcoming investor conferences: TD Cowen 44 th Annual Healthcare Conference, on Wednesday March 6 th at 1:30 pm ET. Barclays 26 th Annual Global Healthcare Conference, on Tuesday March 12 th at 2:35 pm ET. A live webcast of each of these presentations will be available under "Events and... Read More
Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55 Reports full-year revenues of $6.8 billion, GAAP net loss of $(4.7) billion and GAAP diluted EPS of $(12.33); loss primarily driven by mostly non-cash charges of $3.7 billion related to resizing and a tax valuation allowance Reaffirms 2024 expected product sales of approximately $4 billion Expects regulatory approvals... Read More
CAMBRIDGE, MA / ACCESSWIRE / February 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that Stéphane Bancel, Chief Executive Officer, has been elected to the National Academy of Engineering (NAE), broadly known as one of the highest acknowledgments of achievement in the field, in recognition of distinguished contributions to engineering and the "development and manufacturing of pharmaceutical products, including the... Read More
CAMBRIDGE, MA / ACCESSWIRE / February 1, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More
CAMBRIDGE, MA / ACCESSWIRE / January 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it has been recognized on Fortune 's World's Most Admired Companies list as part of its "All-Star" top-50 companies. This annual list is considered one of the leading measures of corporate reputation among global organizations. "We are honored to be recognized among the most admired companies in the world. This marks our first year on... Read More
Company announces product sales for 2023 of approximately $6.7 billion (unaudited); U.S. COVID-19 market share season to date increased to 48% in 2023, up from 37% in 2022 Company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and expectation to break even in 2026 through product launches and disciplined investment Company highlights nine late-stage programs with... Read More
CAMBRIDGE, MA / ACCESSWIRE / December 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced that Jamey Mock, Chief Financial Officer, will present at the 42nd annual J.P. Morgan Healthcare Conference on Monday, January 8th at 6:45 p.m. ET / 3:45 p.m. PT. A live webcast of each presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com . A... Read More
Moderna has submitted marketing authorizations globally for mRNA-1345 and continues to prepare for an expected 2024 marketing launch CAMBRIDGE, MA / ACCESSWIRE / December 15, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced the publication of positive Phase 3 clinical study results evaluating mRNA-1345, its vaccine candidate for respiratory syncytial virus (RSV), in The New England Journal of Medicine . The peer-reviewed... Read More
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant metastasis or death by 62% (HR=0.384 [95% CI, 0.172-0.858]; one-sided nominal p= 0.0077) compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following... Read More
CAMBRIDGE, MA / ACCESSWIRE / December 12, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced changes to its operating model to bring focus to its short- and long-term business goals. The Company is focused on driving continued sales of its COVID-19 vaccine and launching its RSV vaccine in 2024, while also preparing to launch multiple products per year from 2025 forward. The Company has decided to increase executive focus on... Read More
The Company's ESG strategy demonstrates its efforts to advance global health and environmental sustainability, as well as its commitments to employees and communities CAMBRIDGE, MA / ACCESSWIRE / December 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will provide an update on its Environmental, Social and Governance (ESG) strategy at its second ESG Investor Event. Building off its inaugural ESG Day in November 2022, the... Read More
CAMBRIDGE, MA / ACCESSWIRE / November 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host its second virtual ESG investor event at 8:00 a.m. ET on Thursday, December 7, 2023. Moderna's ESG Investor Event will include presentations from management on Moderna's ESG strategy. A live webcast of the event will be available under "Events and Presentations" in the Investors section of the Moderna website.... Read More
CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc . (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: 2023 UBS Global Biopharma Conference on November 9 th at 8:00 a.m. ET. 2023 Jefferies London Healthcare Conference on November 16 th at 8:30 a.m. GMT. 35 th Annual Piper Sandler Healthcare Conference on November 30 th at 12:30 p.m. ET. A live webcast of each... Read More
The Company demonstrates how its integrated Artificial Intelligence ecosystem accelerates innovation at scale and creates value across the enterprise Moderna to present case studies on how the organization is building a real-time AI Company CAMBRIDGE, MA / ACCESSWIRE / November 8, 2023 / Moderna, Inc. (NASDAQ:MRNA) today will unveil its comprehensive AI and digital strategy at its second Digital Investor Event. Building off... Read More
CAMBRIDGE, MA / ACCESSWIRE / November 7, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in BioSpace's 2024 Best Places to Work report for the third consecutive year. "We are proud to be named the best place to work on BioSpace's 2024 ranking for the third year in a row," said Stéphane Bancel, Chief Executive Officer of Moderna. "This recognition is a testament to the unique... Read More
Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion Spikevax U.S. market share to date increased to 45% from 36% in 2022 Company anticipates 2024 revenue of approximately $4 billion and return to growth in 2025 Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven... Read More
New partnership will harness Moderna's mRNA rapid-response platform, clinically validated during the COVID-19 pandemic, to accelerate epidemic and pandemic vaccine development First project will enable rapid pre-clinical testing of antigen designs for high-risk viral families, to advance global outbreak readiness CAMBRIDGE, MA / ACCESSWIRE / October 30, 2023 / The Coalition for Epidemic Preparedness Innovations (CEPI) and... Read More
CAMBRIDGE, MA / ACCESSWIRE / October 26, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as one of the top employers in the global biopharmaceutical industry in Science and Science Careers' 2023 Top Employers Survey for the ninth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility. "We are again honored to be... Read More
mRNA-1083 is Moderna's first respiratory combination vaccine candidate to enter a Phase 3 trial Phase 3 initiation follows data from a Phase 1/2 trial where mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company has multiple programs in Phase 3 development across several areas, including respiratory... Read More
Partnership enables Moderna to leverage Caris' vast library of de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and the delivery of novel medicines to patients IRVING, Texas , Oct. 24, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to... Read More
CAMBRIDGE, MA / ACCESSWIRE / October 19, 2023 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a virtual Digital and AI Investor Event at 8:00 a.m. ET on Wednesday, November 8, 2023. The event will include presentations from management discussing Moderna's digital strategy and the role of AI in accelerating its innovation, scale and value creation. The company will discuss a range of AI applications across... Read More
CAMBRIDGE, MA / ACCESSWIRE / October 12, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 2, 2023 to report its third quarter 2023 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website. Webcast:... Read More
mRNA-1083 showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines Company to begin Phase 3 trial of mRNA-1083 in adults 50 years and above CAMBRIDGE, MA / ACCESSWIRE / October 4, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced positive interim results from the Phase 1/2 trial of mRNA-1083, an investigational combination... Read More
CAMBRIDGE, MA / ACCESSWIRE / September 29, 2023 / Moderna, Inc. (NASDAQ:MRNA) has become aware that TRC Capital Investment Corporation (TRC Capital) has amended its unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price that is now $99.00 per share, down from $107.56 per share under the original offer. TRC Capital's amended offer price of $99.00 per share is lower than... Read More
The positive opinion follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines for autumn/winter 2023 vaccination campaigns Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86, EG.5, and FL.1.5.1 variants CAMBRIDGE, MA /... Read More
Company's flu vaccine, mRNA-1010, met its primary endpoint in Phase 3 trial; separate Phase 1/2 data demonstrated higher HAI titers than Fluzone HD Vaccine pipeline advancing rapidly with Company announcing the completion of RSV BLA filing (mRNA-1345), completion of adult enrollment in the Phase 3 trial of mRNA-1647, a first-in-class vaccine against CMV, and the Phase 3 trial of mRNA-1283, a next-generation COVID-19 vaccine... Read More
Clinical data show robust immune responses across multiple circulating variants, including EG.5, FL.1.5.1, and BA.2.86 Updated vaccine to be available in pharmacies and care settings across the U.S. in the coming days CAMBRIDGE, MA / ACCESSWIRE / September 11, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application(sBLA) for... Read More
CAMBRIDGE, MA / ACCESSWIRE / September 8, 2023 / Moderna, Inc. (Nasdaq:MRNA) has been notified that TRC Capital Investment Corporation (TRC Capital) has made an unsolicited "mini-tender" offer to purchase up to 1,000,000 shares of Moderna's common stock, at an offer price of $107.56 per share. TRC Capital's offer price of $107.56 per share is approximately 4.44% lower than the closing price of Moderna common stock on the... Read More
CAMBRIDGE, MA / ACCESSWIRE / September 6, 2023 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in a fireside chat at Morgan Stanley's 21st Annual Global Healthcare Conference on Tuesday, September 12th at 12:15 p.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com . A replay of the webcast will... Read More
CDC notes that the BA.2.86 (Pirola) variant may be more likely to break through existing immunity from previous vaccination or infection, highlighting the need for vaccination with an updated COVID-19 vaccine for the fall 2023 season Clinical trial data from research assay confirmed Moderna's updated COVID-19 vaccine showed an 8.7 to 11-fold increase in neutralizing antibodies against circulating variants, including BA.2.86,... Read More
CAMBRIDGE, MA / ACCESSWIRE / August 30, 2023 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - R&D Day and Business Updates at 1:00 p.m. ET on Wednesday, September 13, 2023. The event will include presentations from management discussing Moderna's development and commercial strategy and key business considerations. A live webcast of the presentation will be available under "Events and... Read More
Updated COVID-19 vaccine effectively targets EG.5, a dominant variant of concern, as well as the rapidly spreading FL 1.5.1 variant Updated vaccine expected to be available, pending approval, in coming weeks for fall vaccination season CAMBRIDGE, MA / ACCESSWIRE / August 17, 2023 / Moderna, Inc. (NASDAQ:MRNA) today announced that preliminary clinical trial data confirm its updated COVID-19 vaccine for the fall 2023... Read More
Study participants include children up to and including 36 months who attend group child care and early childhood education settings located in Worcester and Cambridge WORCESTER, Mass. , Aug. 14, 2023 /PRNewswire/ -- UMass Chan Medical School today announced it will begin enrolling participants at group child care and early childhood education settings in Worcester and Cambridge to examine the impact of cytomegalovirus (CMV)... Read More
Second quarter 2023 revenues of $0.3 billion; net loss of $1.4 billion and loss per share of $3.62 Company expecting 2023 COVID-19 vaccine sales of $6 billion to $8 billion, dependent on U.S. vaccination rates Company submitted its investigational RSV vaccine to several regulators globally ahead of potential 2024 launch With its partner Merck, the Company began Phase 3 trial of mRNA-4157, its individualized neoantigen... Read More
CAMBRIDGE, MA / ACCESSWIRE / July 13, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 3, 2023 to report its second quarter 2023 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and... Read More
Moderna has submitted marketing authorization applications for the investigational RSV vaccine, mRNA-1345, with the European Medicines Agency, Swissmedic, and the Therapeutic Goods Administration in Australia The Company has also initiated a rolling submission of a Biologics License Application to the U.S. Food and Drug Administration for mRNA-1345 mRNA-1345 met primary efficacy endpoints, demonstrating vaccine efficacy of... Read More
The filing follows the recommendation from regulators and global public health bodies to develop monovalent XBB.1.5 COVID-19 vaccines Pending approval, Moderna's updated COVID-19 vaccine will be available for fall vaccination with ample and timely supply Preliminary clinical data show that the company's XBB1.5 monovalent vaccine induces an immune response against viruses of the XBB lineage CAMBRIDGE, MA / ACCESSWIRE / July... Read More
Health Canada submission follows international recommendations to develop monovalent XBB.1.5 COVID-19 vaccines Moderna is prepared to deliver updated COVID-19 vaccines in time for the fall 2023 vaccination season TORONTO , June 29, 2023 /CNW/ - Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has initiated the filing of a rolling New Drug... Read More
Preliminary clinical data demonstrated a robust immune response by the company's XBB.1.5 monovalent vaccine against XBB descendent lineage viruses Pending authorization, Moderna's updated COVID-19 vaccine would be available in time for fall vaccination Supply readiness follows months of manufacturing to ensure timely and ample supply CAMBRIDGE, MA / ACCESSWIRE / June 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology... Read More
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA alone The DMFS results, a key secondary endpoint of the Phase 2b KEYNOTE-942 study, will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Companies plan to initiate a Phase 3 study in the adjuvant setting in... Read More
CAMBRIDGE, MA / ACCESSWIRE / June 1, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming investor conferences: 2023 Jefferies Healthcare Conference on Thursday, June 8 th at 10:30 a.m. ET 44 th Annual Goldman Sachs Global Healthcare Conference on Wednesday, June 14 th at 4:40 p.m. PST A live webcast... Read More
ASCO presentations on Saturday, June 3 at 4:30pm CDT and Monday, June 5 at 3:00pm CDT Moderna to host investor event via webcast on Monday, June 5 at 6pm CDT CAMBRIDGE, MA / ACCESSWIRE / May 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy,... Read More
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement To date, mRNA-3927 has been generally well-tolerated at the doses administered, with encouraging early signs of dose-dependent pharmacology and potential clinical benefits No occurrence of dose-limiting toxicities or study discontinuations due to drug-related treatment-emergent adverse events (TEAEs) More than 280 doses of... Read More
Vaccines manufactured at Moderna's state-of-the-art Canadian mRNA facility to be prepared and packaged at Novocol's Ontario -based facility Fill-finish agreement will secure domestic end-to-end vaccine production and ensures rapid response capabilities for future pandemic readiness for Canadians TORONTO , May 4, 2023 /CNW/ - Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics... Read More
First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19 Company in negotiations for new orders for fall of 2023 in U.S., Japan, and EU, in addition to reiterating 2023 minimum sales expectations of approximately $5.0 billion from previously announced COVID-19 vaccine Advanced Purchase Agreements Company preparing for potential 2024 commercial launch of its investigational RSV... Read More
After completing enrollment in 5 dose cohorts, and with no dose-limiting safety signals observed to date by the independent DSMB, the Phase 1/2 trial of mRNA-3927 advances to the dose-expansion phase to determine a recommended dose CAMBRIDGE, MA / ACCESSWIRE / May 3, 2023 / Moderna,Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that an abstract reporting... Read More
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna's Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta, U.S. The Philippines was selected due to its mature global business service environment, favorable infrastructure and business climate, and accessibility of broad and diverse talent The Company also plans to establish a commercial presence in the Philippines... Read More
CAMBRIDGE, MA / ACCESSWIRE / April 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 to report its first quarter 2023 financial results, and provide a corporate update. A live webcast of the call will be available under "Events and... Read More
Moderna invests in developing quantum computing skills and exploring the use of quantum computing in developing future mRNA medicines Agreement with IBM includes investments in generative AI to improve product design CAMBRIDGE, MA and ARMONK, NY / ACCESSWIRE / April 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and IBM (NYSE:IBM) today announced an... Read More
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Results from the Phase 2b KEYNOTE-942 trial selected for AACR press program Companies will initiate a Phase 3 study in patients with adjuvant melanoma in 2023, and rapidly expand to additional tumor types, including... Read More
Next-generation, refrigerator-stable COVID-19 vaccine candidate, mRNA-1283, has dosed first participant in its Phase 3 trial Company expects to file for approval of its investigational RSV vaccine candidate, mRNA-1345, this quarter Company's first influenza candidate, mRNA-1010, did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial and the... Read More
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / April 6, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced... Read More
Facility to enable access to manufactured mRNA vaccines for Kenya and the African continent, providing health security and building upon Moderna's global public health commitments The facility will be capable of producing up to 500 million doses each year CAMBRIDGE, MA & NAIROBI, KENYA / ACCESSWIRE / March 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and... Read More
CAMBRIDGE, MA / ACCESSWIRE / March 24, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will present its Vaccines Day for analysts and investors at 8:00 a.m. ET on Tuesday, April 11, 2023. Moderna's Vaccines Day will include presentations from management and key opinion leaders (KOLs) on Moderna's mRNA vaccines and key... Read More
CAMBRIDGE, MA / ACCESSWIRE / March 14, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that two abstracts on mRNA-4157/V940 an investigational mRNA personalized cancer vaccine, have been accepted for presentation at the 2023 American Association of Cancer Research (AACR) Annual Meeting being held April 14-19 in Orlando, FL. mRNA-4157/V940... Read More
Expansion includes new West Coast offices in South San Francisco, California and Seattle, Washington New offices complement existing locations in Cambridge, MA; Norwood, MA; Atlanta, GA; Bethesda, MD; and Princeton, NJ Moderna currently has offices in 17 locations worldwide Company plans to hire approximately 2,000 new employees in 2023 CAMBRIDGE, MA / ACCESSWIRE / March 10, 2023 / Moderna, Inc. , (NASDAQ:MRNA) a... Read More
CAMBRIDGE, MA / ACCESSWIRE / February 28, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6 th at 9:10 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna... Read More
Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61 Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12 Company reiterating approximately $5 billion in COVID-19 sales contracted for delivery in 2023 and expecting additional sales from key markets Company will file for regulatory approval for mRNA-1345, Moderna's... Read More
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE / February 22, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in... Read More
Collaboration to combine Moderna's mRNA platform with Life Edit's proprietary gene editing technologies, including base editing capabilities Multi-target collaboration to advance potentially life-transformative or curative therapies for some of the most challenging genetic diseases Life Edit to receive upfront cash payment, research, and preclinical funding, and is eligible to receive milestone payments with tiered royalties... Read More
The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4/5)) are currently authorized for use in individuals 18 years of age and older in Canada Both bivalents have been shown to trigger a superior antibody response compared to a booster dose of mRNA-1273, the... Read More
mRNA-1010 demonstrated superiority on seroconversion rates for A/H3N2 and A/H1N1, superiority on geometric mean titer ratios for A/H3N2, and non-inferiority on geometric mean titer ratios for A/H1N1 Non-inferiority was not met for seroconversion rates and geometric mean titer ratios for the influenza B/Victoria- and B/Yamagata-lineage strains mRNA-1010 showed an acceptable safety and tolerability profile Separate parallel... Read More
CAMBRIDGE, MA / ACCESSWIRE / February 2, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 23, 2023 to report its fourth quarter and full year 2022 financial results, and provide a corporate update. A live webcast of the call will be available under... Read More
Designation based on positive topline data from the ConquerRSV Phase 3 pivotal efficacy trial, which demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults CAMBRIDGE, MA / ACCESSWIRE / January 30, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced mRNA-1345, an... Read More
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults mRNA-1345 was generally well-tolerated, with no safety concerns identified by the DSMB Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval CAMBRIDGE, MA, ACCESSWIRE / January 17, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering... Read More
COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited) Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for 2023 Company continues to scale with 48 programs in development, including 36 in ongoing clinical studies, and is increasing R&D investment to an expected $4.5 billion for 2023 Pivotal Phase 3 RSV study of mRNA-1345 in older... Read More
Collaboration will combine Moderna's mRNA technology with CytomX's Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million upfront payment with the potential for additional research, milestone, and royalty payments CAMBRIDGE, MA and SOUTH SAN FRANCISCO, CA / ACCESSWIRE / January 5, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering... Read More
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines Acquisition will bolster Moderna's suite of platform technologies CAMBRIDGE, MA and TOKYO, JAPAN / ACCESSWIRE / January 4, 2023 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA... Read More
CAMBRIDGE, MA / ACCESSWIRE / January 3, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will present an update on the Company and its pipeline of mRNA development programs at the 41st annual J.P. Morgan Healthcare Conference on Monday, January 9th at 5:15 p.m. ET. A live webcast of the presentation will be... Read More
Facility to enable access to domestically manufactured mRNA respiratory vaccines, pending regulatory assessment and licensure The ten-year strategic partnership is expected to provide the UK public with response capabilities to ensure future preparedness in light of the COVID-19 pandemic Moderna is expanding its presence in the UK through investments in R&D activities and capabilities CAMBRIDGE, MA / ACCESSWIRE / December... Read More
Newly created role will have responsibility for commercial efforts in Europe, Middle East and Canada CAMBRIDGE, MA / ACCESSWIRE / December 20, 2022 / Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Chantal Friebertshäuser as Senior Vice President, Commercial, Europe, Middle East and Canada effective January 1, 2023. Ms.... Read More
The recommendation is based on clinical data for Moderna's bivalent Omicron-targeting COVID-19 vaccine, mRNA.1273.214 Moderna's bivalent Omicron-targeting COVID-19 vaccines (mRNA.1273.214 (BA.1) & mRNA.1273.222 (BA.4-5)) are approved for use in individuals 12 years of age and older in the European Union Both bivalents have been shown to trigger a superior antibody response compared to a booster dose of mRNA-1273, the... Read More
mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death compared to KEYTRUDA monotherapy in stage III/IV melanoma patients with high risk of recurrence following complete resection Results are the first demonstration of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial Companies... Read More
mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccines CAMBRIDGE, MA / ACCESSWIRE / December 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA)... Read More
Current Chief Digital Officer, Marcello Damiani, to retire in March CAMBRIDGE, MA / ACCESSWIRE / December 7, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of Brad Miller as Chief Information Officer effective January 3. Mr. Miller will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stéphane... Read More
CAMBRIDGE, MA / ACCESSWIRE / November 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, Dec. 1 st at 9:00 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the... Read More
CAMBRIDGE, MA / ACCESSWIRE / November 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of David Jiménez as General Manager, United States, effective November 21, 2022. Mr. Jiménez will be responsible for commercial efforts in the United States, reporting to Arpa Garay, Moderna's Chief Commercial Officer. "David has... Read More
Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.222 (Spikevax Bivalent Original/Omicron BA.4-5) in adults 18 years and older. Spikevax Bivalent... Read More
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host its first virtual ESG Day for analysts and investors at 9:00 a.m. ET on Thursday, November 10. Moderna's ESG Day will include presentations from management on Moderna's mission and ESG journey, including a review of its first ESG report published in June. A live webcast will be... Read More
Moderna, Inc. , (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it was ranked one of the top employers in the global biopharmaceutical industry by Science and Science Careers' 2022 Top Employers Survey for the eighth consecutive year. Moderna was ranked no. 7 on the list this year and was recognized for its commitment to innovative leadership, respect for... Read More
Announcement follows CHMP's previous decision to issue a positive opinion recommending marketing authorization for Moderna's COVID-19 vaccine to include children 6 years of age and older Two-dose series takes one month to complete, with similar vaccine efficacy estimates against Omicron to those seen in adults Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines,... Read More
Data indicate durable immune response from bivalent booster after three months of follow-up mRNA-1273.214 also demonstrated potent response to Omicron BA.2.75 Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214. Ninety days after administration as a fourth booster dose in... Read More
Given the sufficient supply of COVID-19 vaccines globally, Moderna & Gavi have mutually agreed to cancel remaining pending orders under the current COVID-19 vaccine supply agreement for 2022 Gavi and Moderna have agreed to create a new framework that would enable Gavi to purchase up to 100 million doses of updated variant-specific COVID-19 vaccines in 2023, with all doses offered at Moderna's lowest-tiered price Moderna,... Read More
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 3, 2022 to report its third quarter 2022 financial results, and provide a corporate update. To access the live conference call via telephone, please register at the link below. Once registered, dial-in numbers... Read More
mRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron Variant Authorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccine Candidates Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/BA.5... Read More
Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 2022 Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that Merck has exercised its option to jointly develop and... Read More
Option exercised on undisclosed immune-oncology target following evaluation period by Moderna Autolus receives option exercise fee, with potential for development milestone payments plus royalties Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programed T cell therapies, today announces that Moderna (MRNA), a biotechnology company pioneering messenger RNA (mRNA)... Read More
Juan Andres Appointed to President, Strategic Partnerships and Enterprise Expansion Jerh Collins Joins Moderna as Chief Technical Operations and Quality Officer to Succeed Juan Andres Moderna, Inc. , (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that the Company has expanded the Executive Committee to prepare for multiple upcoming new product launches.... Read More
Filing follows approval of Spikevax bivalent Original/Omicron BA.1 (mRNA-1273.214), a bivalent booster vaccine targeting the Omicron BA.1 subvariant, in September Moderna's Omicron-targeting bivalent boosters now authorized in the United States, Australia, Canada, Europe, Japan, South Korea, Switzerland, Singapore, Taiwan, and the UK Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA)... Read More
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change to a new drug application for its Omicron-targeting bivalent COVID-19 booster, mRNA-1273.214 (Spikevax Bivalent Original/Omicron BA.1). Spikevax Bivalent Original/Omicron contains... Read More
Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose Ba1ance trial shows mRNA-3745 was well tolerated to date, with encouraging early signs of potential for clinical benefit Moderna announces a new development... Read More
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stephen Hoge, M.D., President, will participate in a fireside chat at the Morgan Stanley 20 th Annual Global Healthcare Conference on Tuesday, September 13 th at 10:00 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the... Read More
mRNA-1273.214 is the first Omicron-targeting bivalent COVID-19 booster vaccine approved in Canada Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Approval follows agreement with the Government of Canada to supply 12 million doses of Omicron-targeting bivalent COVID-19 boosters Moderna, Inc . (NASDAQ:MRNA), a... Read More
Study results show mRNA-1273.214 has demonstrated significantly higher antibody titers against Omicron BA.1 and BA.4/5 subvariants when compared with mRNA-1273 Positive recommendation follows recent amendment to European Commission (EC) COVID-19 vaccine agreement to supply Omicron-targeting bivalent candidates In addition to the CHMP positive opinion, Moderna has received approvals for mRNA-1273.214 in Australia,... Read More
Moderna's Bivalent Booster Shots to be Available Nationwide In Coming Days mRNA-1273.222 Targets BA.4/.5 Strains of Omicron Variant Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its BA.4/.5 Omicron-targeting bivalent COVID-19 booster... Read More
Australia becomes among the first countries in the world to approve the use of a next-generation bivalent COVID-19 vaccine mRNA-1273.214, an Omicron-containing bivalent vaccine, has demonstrated significantly higher antibody titers against all tested variants, including Omicron BA.1 and BA.4/5 subvariants Moderna expects to supply mRNA-1273.214 to Australia in September Moderna, Inc. (NASDAQ:MRNA), a biotechnology company... Read More
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host its in-person and virtual R&D Day at 9:00 a.m. ET on Thursday, September 8, 2022. Moderna's R&D Day will feature presentations from Stéphane Bancel, Chief Executive Officer, Stephen Hoge M.D., President, and Moderna clinical team leaders. A live webcast will be available under " Events... Read More
Amneal Pharmaceuticals

COPYRIGHT ©2023 HEALTH STOCKS HUB